Noncoding RNAs in drug-resistant pancreatic cancer: A review

[Display omitted] •A great number of dysregulated noncoding RNAs are correlated with drug resistance of pancreatic cancer.•Noncoding RNAs have an important regulatory role in the mechanism of pancreatic cancer drug resistance.•Noncoding RNAs can be served as prognostic markers and novel therapeutic...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicine & pharmacotherapy 2020-11, Vol.131, p.110768-110768, Article 110768
Main Authors: Lin, Zhengjun, Lu, Shiyao, Xie, Xubin, Yi, Xuyang, Huang, He
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - pharmacology
Biomarkers, Tumor - genetics
Circular RNA
Drug resistance
Drug Resistance, Neoplasm - genetics
Humans
Long non-coding RNA
MicroRNA
Pancreatic cancer
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - genetics
Pancreatic Neoplasms - pathology
Prognosis
RNA, Untranslated - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] •A great number of dysregulated noncoding RNAs are correlated with drug resistance of pancreatic cancer.•Noncoding RNAs have an important regulatory role in the mechanism of pancreatic cancer drug resistance.•Noncoding RNAs can be served as prognostic markers and novel therapeutic targets in pancreatic cancer. Pancreatic cancer is the fourth-leading cause of cancer-related deaths and is expected to be the second-leading cause of cancer-related deaths in Europe and the United States by 2030. The high fatality rate of pancreatic cancer is ascribed to untimely diagnosis, early metastasis and limited responses to both chemotherapy and radiotherapy. Although gemcitabine, 5-fluorouracil and some other drugs can profoundly improve patient prognosis, most pancreatic cancer patients eventually develop drug resistance, leading to poor clinical outcomes. The underlying mechanisms of pancreatic cancer drug resistance are complicated and inconclusive. Interestingly, accumulating evidence has demonstrated that different noncoding RNAs (ncRNAs), such as microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), play a crucial role in pancreatic cancer resistance to chemotherapy reagents. In this paper, we systematically summarize the molecular mechanism underlying the influence of ncRNAs on the generation and development of drug resistance in pancreatic cancer and discuss the potential role of ncRNAs as prognostic markers and new therapeutic targets for pancreatic cancer.
ISSN:0753-3322
1950-6007
DOI:10.1016/j.biopha.2020.110768